StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ultragenyx Pharmaceutical operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ultragenyx Pharmaceutical's operating income for the twelve months ending Jun 30, 2026 was -$528.17M. For fiscal 2025 it was -$535.00M. The highest annual figure on record is -$15.99M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$535.00M–
FY2024Dec 31, 2024-$536.00M–
FY2023Dec 31, 2023-$569.00M–
FY2022Dec 31, 2022-$648.92M–
FY2021Dec 31, 2021-$381.74M–
FY2020Dec 31, 2020-$330.12M–
FY2019Dec 31, 2019-$424.17M–
FY2018Dec 31, 2018-$371.37M–
FY2017Dec 31, 2017-$328.94M–
FY2016Dec 31, 2016-$248.01M–
FY2015Dec 31, 2015-$147.74M–
FY2014Dec 31, 2014-$56.78M–
FY2013Dec 31, 2013-$32.28M–
FY2012Dec 31, 2012-$15.99M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$75.00M–
Q1 FY2026Mar 31, 2026-$169.00M–
Q4 FY2025Dec 31, 2025-$113.28M–
Q3 FY2025Sep 30, 2025-$170.89M–
Q2 FY2025Jun 30, 2025-$108.00M–
Q1 FY2025Mar 31, 2025-$143.00M–
Q4 FY2024Dec 31, 2024-$122.31M–
Q3 FY2024Sep 30, 2024-$131.99M–
Q2 FY2024Jun 30, 2024-$116.36M–
Q1 FY2024Mar 31, 2024-$165.35M–
Q4 FY2023Dec 31, 2023-$121.84M–
Q3 FY2023Sep 30, 2023-$145.10M–
Q2 FY2023Jun 30, 2023-$147.96M–
Q1 FY2023Mar 31, 2023-$154.11M–
Q4 FY2022Dec 31, 2022-$145.63M–
Q3 FY2022Sep 30, 2022-$225.07M–
Q2 FY2022Jun 30, 2022-$141.59M–
Q1 FY2022Mar 31, 2022-$136.63M–
Q4 FY2021Dec 31, 2021-$102.56M–
Q3 FY2021Sep 30, 2021-$89.83M–
Q2 FY2021Jun 30, 2021-$82.78M–
Q1 FY2021Mar 31, 2021-$106.57M–
Q4 FY2020Dec 31, 2020-$96.08M–
Q3 FY2020Sep 30, 2020-$50.32M–
Q2 FY2020Jun 30, 2020-$63.06M–
Q1 FY2020Mar 31, 2020-$120.67M–
Q4 FY2019Dec 31, 2019-$94.45M–
Q3 FY2019Sep 30, 2019-$118.03M–
Q2 FY2019Jun 30, 2019-$112.47M–
Q1 FY2019Mar 31, 2019-$99.21M–
Q4 FY2018Dec 31, 2018-$90.34M–
Q3 FY2018Sep 30, 2018-$89.65M–
Q2 FY2018Jun 30, 2018-$94.90M–
Q1 FY2018Mar 31, 2018-$96.49M–
Q4 FY2017Dec 31, 2017-$96.83M–
Q3 FY2017Sep 30, 2017-$83.71M–
Q2 FY2017Jun 30, 2017-$78.44M–
Q1 FY2017Mar 31, 2017-$69.95M–
Q4 FY2016Dec 31, 2016-$70.55M–
Q3 FY2016Sep 30, 2016-$65.78M–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?